Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography Time-Of-Flight mass spectrometry

Metabolites

Volumn 5, Issue 2, 2015, Pages 192-210

  Miyamoto, Suzanne ^a   Taylor, Sandra L ^b   Barupal, Dinesh K ^c,g   Taguchi, Ayumu ^d   Wohlgemuth, Gert ^c   Wikoff, William R ^c   Yoneda, Ken Y ^e   Gandara, David R ^a   Hanash, Samir M ^d   Kim, Kyoungmi ^b   Fiehn, Oliver ^c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Blood; Lung cancer; Mass spectrometry; Metabolomics

Indexed keywords

ETHANOLAMINE; GLUTAMIC ACID; GLYCEROL; HISTIDINE; LACTIC ACID; LYSINE; MALTOSE; PALMITIC ACID; TRYPTOPHAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER MORTALITY; CHEMOMETRICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GENE MAPPING; HUMAN; LUNG CANCER; MALE; METABOLITE; METABOLOMICS; MIDDLE AGED; TIME OF FLIGHT MASS SPECTROMETRY; VERY ELDERLY;

EID: 85016919890     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo5020192     Document Type: Article

References (48)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
3. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584-594.
4. National Lung Screening Trial Research, T.; Aberle, D.R.; Berg, C.D.; Black, W.C.; Church, T.R.; Fagerstrom, R.M.; Galen, B.; Gareen, I.F.; Gatsonis, C.; Goldin, J.; et al. The national lung screening trial: Overview and study design. Radiology 2011, 258, 243-253.
5. Goulart, B.H.; Bensink, M.E.; Mummy, D.G.; Ramsey, S.D. Lung cancer screening with low-dose computed tomography: Costs, national expenditures, and cost-effectiveness. J. Natl. Compr. Canc. Netw. 2012, 10, 267-275.
6. Louie, A.V.; Rodrigues, G.; Olsthoorn, J.; Palma, D.; Yu, E.; Yaremko, B.; Ahmad, B.; Aivas, I.; Gaede, S. Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era. Radiother. Oncol.: J. Eur. Soc. Ther. Radiol. Oncol. 2010, 95, 166-171.
7. Bigbee, W.L.; Gopalakrishnan, V.; Weissfeld, J.L.; Wilson, D.O.; Dacic, S.; Lokshin, A.E.; Siegfried, J.M. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by ct screening. J. Thorac. Oncol. 2012, 7, 698-708.
8. Tsay, J.C.; DeCotiis, C.; Greenberg, A.K.; Rom, W.N., Current readings: Blood-based biomarkers for lung cancer. Semin. Thorac. Cardiovasc. Surg. 2013, 25, 328-334.
9. Deberardinis, R.J.; Sayed, N.; Ditsworth, D.; Thompson, C.B. Brick by brick: Metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18, 54-61.
10. Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y.; et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457, 910-914.
11. Denkert, C.; Budczies, J.; Kind, T.; Weichert, W.; Tablack, P.; Sehouli, J.; Niesporek, S.; Konsgen, D.; Dietel, M.; Fiehn, O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006, 66, 10795-10804.
12. Urayama, S.; Zou, W.; Brooks, K.; Tolstikov, V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 2010, 24, 613-620.
13. Fan, L.; Zhang, W.; Yin, M.; Zhang, T.; Wu, X.; Zhang, H.; Sun, M.; Li, Z.; Hou, Y.; Zhou, X.; et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a uplc/qtof/ms platform. Acta Oncol. 2012, 51, 473-479.
14. Slupsky, C.M.; Steed, H.; Wells, T.H.; Dabbs, K.; Schepansky, A.; Capstick, V.; Faught, W.; Sawyer, M.B. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 2010, 16, 5835-5841.
15. Woo, H.M.; Kim, K.M.; Choi, M.H.; Jung, B.H.; Lee, J.; Kong, G.; Nam, S.J.; Kim, S.; Bai, S.W.; Chung, B.C. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin. Chim. Acta 2009, 400, 63-69.
16. Yu, L.; Aa, J.; Xu, J.; Sun, M.; Qian, S.; Cheng, L.; Yang, S.; Shi, R. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J. Gastroenterol. Hepatol. 2011, 26, 1290-1297.
17. Maeda, J.; Higashiyama, M.; Imaizumi, A.; Nakayama, T.; Yamamoto, H.; Daimon, T.; Yamakado, M.; Imamura, F.; Kodama, K. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: A case control study. BMC Cancer 2010, 10, 690.
18. Amon, L.M.; Pitteri, S.J.; Li, C.I.; McIntosh, M.; Ladd, J.J.; Disis, M.; Porter, P.; Wong, C.H.; Zhang, Q.; Lampe, P.; et al. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of er+ breast cancer. Cancer Res. 2012, 72, 1935-1942.
19. Buckendahl, A.C.; Budczies, J.; Fiehn, O.; Darb-Esfahani, S.; Kind, T.; Noske, A.; Weichert, W.; Sehouli, J.; Braicu, E.; Dietel, M.; et al. Prognostic impact of amp-activated protein kinase expression in ovarian carcinoma: Correlation of protein expression and gc/tof-ms-based metabolomics. Oncol. Rep. 2011, 25, 1005-1012.
20. Suhre, K.; Shin, S.Y.; Petersen, A.K.; Mohney, R.P.; Meredith, D.; Wagele, B.; Altmaier, E.; CardioGram; Deloukas, P.; Erdmann, J.; et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477, 54-60.
21. Serkova, N.J.; Glunde, K. Metabolomics of cancer. Methods Mol. Biol. 2009, 520, 273-295.
22. Lane, A.N.; Fan, T.W.; Bousamra, M., 2nd; Higashi, R.M.; Yan, J.; Miller, D.M. Stable sotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS 2011, 15, 173-182.
23. Mardia, K.V.; Kent, J.T.; Bibby, J.M. Multivariate Analysis; Academic Press: London, UK; New York, NY, USA, 1979; p 15.
24. Wold, S. Exponentially weighted moving principal components-analysis and projections to latent structures. Chemometr. Intell. Lab. Syst. 1994, 23, 149-161.
25. Kind, T.; Wohlgemuth, G.; Lee do, Y.; Lu, Y.; Palazoglu, M.; Shahbaz, S.; Fiehn, O. Fiehnlib: Mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 2009, 81, 10038-10048.
26. Kumari, S.; Stevens, D.; Kind, T.; Denkert, C.; Fiehn, O. Applying in-silico retention index and mass spectra matching for identification of unknown metabolites in accurate mass gc-tof mass spectrometry. Anal. Chem. 2011, 83, 5895-5902.
27. Kind, T.; Fiehn, O. Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinf. 2007, 8, 105.
28. Wen, T.; Gao, L.; Wen, Z.; Wu, C.; Tan, C.S.; Toh, W.Z.; Ong, C.N. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol. Biosyst. 2013, 9, 2370-2378.
29. Cascino, A.; Muscaritoli, M.; Cangiano, C.; Conversano, L.; Laviano, A.; Ariemma, S.; Meguid, M.M.; Rossi Fanelli, F. Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res. 1995, 15, 507-510.
30. Miyagi, Y.; Higashiyama, M.; Gochi, A.; Akaike, M.; Ishikawa, T.; Miura, T.; Saruki, N.; Bando, E.; Kimura, H.; Imamura, F.; et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 2011, 6, e24143.
31. Rossi Fanelli, F.; Cangiano, C.; Ceci, F.; Cellerino, R.; Franchi, F.; Menichetti, E.T.; Muscaritoli, M.; Cascino, A. Plasma tryptophan and anorexia in human cancer. Eur. J. Cancer Clin. Oncol. 1986, 22, 89-95.
32. Rossi Fanelli, F.; Cangiano, C.; Muscaritoli, M.; Conversano, L.; Torelli, G.F.; Cascino, A. Tumor-induced changes in host metabolism: A possible marker of neoplastic disease. Nutrition 1995, 11, 595-600.
33. Rocha, C.M.; Carrola, J.; Barros, A.S.; Gil, A.M.; Goodfellow, B.J.; Carreira, I.M.; Bernardo, J.; Gomes, A.; Sousa, V.; Carvalho, L.; et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J. Proteome Res. 2011, 10, 4314-4324.
34. Zhu, C.S.; Pinsky, P.F.; Cramer, D.W.; Ransohoff, D.F.; Hartge, P.; Pfeiffer, R.M.; Urban, N.; Mor, G.; Bast, R.C., Jr.; Moore, L.E.; et al. A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prev. Res. 2011, 4, 375-383.
35. Cramer, D.W.; Bast, R.C., Jr.; Berg, C.D.; Diamandis, E.P.; Godwin, A.K.; Hartge, P.; Lokshin, A.E.; Lu, K.H.; McIntosh, M.W.; Mor, G.; et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. 2011, 4, 365-374.
36. Wedge, D.C.; Allwood, J.W.; Dunn, W.; Vaughan, A.A.; Simpson, K.; Brown, M.; Priest, L.; Blackhall, F.H.; Whetton, A.D.; Dive, C.; et al. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal. Chem. 2011, 83, 6689-6697.
37. Fan, T.W.; Lane, A.N.; Higashi, R.M.; Farag, M.A.; Gao, H.; Bousamra, M.; Miller, D.M. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 2009, 8, 41.
38. Kanehisa, M.; Goto, S.; Sato, Y.; Furumichi, M.; Tanabe, M. Kegg for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012, 40, D109-D114.
39. Kanehisa, M.; Goto, S.; Furumichi, M.; Tanabe, M.; Hirakawa, M. Kegg for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38, D355-D360.
40. Barupal, D.K.; Haldiya, P.K.; Wohlgemuth, G.; Kind, T.; Kothari, S.L.; Pinkerton, K.E.; Fiehn, O. Metamapp: Mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinf. 2012, 13, 99.
41. Pisters, P.W.; Pearlstone, D.B. Protein and amino acid metabolism in cancer cachexia: Investigative techniques and therapeutic interventions. Crit. Rev. Clin. Lab Sci. 1993, 30, 223-272.
42. Sozzi, G.; Boeri, M.; Rossi, M.; Verri, C.; Suatoni, P.; Bravi, F.; Roz, L.; Conte, D.; Grassi, M.; Sverzellati, N.; et al. Clinical utility of a plasma-based mirna signature classifier within computed tomography lung cancer screening: A correlative mild trial study. J. Clin. Oncol. 2014, 32, 768-773.
43. Weckwerth, W.; Wenzel, K.; Fiehn, O. Process for the integrated extraction, identification and quantification of metabolites, proteins and rna to reveal their co-regulation in biochemical networks. Proteomics 2004, 4, 78-83.
44. Fiehn, O. Extending the breadth of metabolite profiling by gas chromatography coupled to mass spectrometry. Trends Anal. Chem. 2008, 27, 261-269.
45. Kind, T.; Tolstikov, V.; Fiehn, O.; Weiss, R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 2007, 363, 185-195.
46. Scholz, M.; Fiehn, O. Setupx-A public study design database for metabolomic projects. Pac. Symp. Biocomput. 2007, 363, 169-180.
47. Boulesteix, A.L.; Strimmer, K. Partial least squares: A versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 2007, 8, 32-44.
48. R Development Core Team. The R Stats Package. Available online: https://stat.ethz.ch/R-manual/R-patched/library/stats/html/00Index.html (accessed on 31 March 2015).